Hospitals are in limbo as they await Medicare’s preliminary decision on whether it will cover Aduhelm; that ruling is expected in January with a final decision anticipated in April. As they await guidance, some health systems are reviewing Biogen’s controversial Alzheimer’s drug on their own.
Read the full post on Becker's Hospital Review - Healthcare News
